Adyuvancia en melanoma: terapia dirigida con Dabra + Trame en pacientes BRAF con mutación V600

15 / 36

Common AEs (≥ 15% of patients)
15
AEs, n (%)
Dabrafenib + Trametinib
n = 435
Placebo
n = 432
Any Grade Grade 3/4 Any Grade Grade 3/4
Rash 106 (24) 0 47 (11) 1 (< 1)
Cough 73 (17) 0 33 (8) 0
Myalgia 70 (16) 1 (< 1) 40 (9) 0
ALT increase 67 (15) 16 (4) 6 (1) 1 (< 1)
Influenza-like illness 67 (15) 2 (< 1) 29 (7) 0
a All cause.
AE, adverse event; ALT, alanine aminotransferase.
Atkinson V, et al. ESMO 2018